A significant reduction in the risk of nocturnal hypoglycemia (≤70 mg/dL) was documented in the EDITION 4 trial (−18%) over the BL to week 8 period, but no differences were found between Glar-300 and Glar-100 when the risk of hypoglycemia according to the time of administration of basal insulin was analyzed (morning or evening). The gene discussed is INS; the disease is Hypoglycemia.